← Eichor
Study identifier: NCT05899842 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Routine Versus Symptomatic Protein Pump Inhibitor Therapy for Prevention of Gastroesophageal Reflux After Per Oral Endoscopic Myotomy for Esophageal Achalasia

Condition: Esophageal Achalasia  ·  Sponsor: Centre Hospitalier Universitaire de Nīmes

PhaseNA
Planned participants132
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Per Oral Endoscopic Myotomy (POEM) is a treatment of choice for achalasia with an excellent safety and efficacy profile. There is a high rate of esophagitis related to gastroesophageal reflux following this procedure. There is no recommendation on the prescription of protein pump inhibitors (PPI) after the procedure and no study has studied the benefit of systematic prescription of PPI after POEM for achalasia. The study authors hypothesize that routine PPI prescribing post-POEM for 12 months would reduce the rate of esophageal acid exposure compared to a symptom-based prescribing strategy.

This description comes directly from the study's public registry record.

Talk to the study team

Antoine Debourdeau  ·  06.68.31.94.89  ·  a-debourdeau@chu-montpellier.fr

Always discuss trial participation with your own doctor first.

Locations (4)

AP-HMMarseille, FranceRecruiting
CHU de MontpellierMontpellier, FranceRecruiting
Clinique mutualiste BeausoleilMontpellier, FranceRecruiting
CHU de NîmesNîmes, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05899842